Immunodiagnostic Systems

IDS is a global medical diagnostics business dedicated to the development and provision of innovative automated and manual assays. Our development focus is in the clinical areas of bone and calcium metabolism, growth, hypertension and chronic kidney disease. Our IDS-iSYS system is designed with the flexibility to accommodate unique and challenging requirements, the IDS-iSYS automation brings testing efficiency and uncompromised quality to specialty immunoassay testing. IDS provides a compact bench top system that fully automates immunoassay testing. IDS has its global headquarters in the UK, and has subsidiaries in the USA, Germany, France, and Denmark. Other markets, including key diagnostic markets of Spain, Italy, Australia, and Japan, are serviced by a network of highly qualified and experienced distributors within each territory.
Type
Public
HQ
Boldon Colliery, GB
Founded
1977
Size (employees)
328 (est)-2%
Website
idsplc.com
Immunodiagnostic Systems was founded in 1977 and is headquartered in Boldon Colliery, GB

Immunodiagnostic Systems Office Locations

Immunodiagnostic Systems has offices in Boldon Colliery, Gaithersburg, Paris, Frankfurt and in 1 other location
Boldon Colliery, GB (HQ)
10 Didcot Way, Boldon Business Park Tyne & Wear

Immunodiagnostic Systems Data and Metrics

Immunodiagnostic Systems Financial Metrics

Immunodiagnostic Systems's revenue was reported to be £38.3 m in FY, 2016 which is a 16% decrease from the previous period.
£, GBP

Revenue (FY, 2016)

38.3 m

Revenue growth (FY, 2015 - FY, 2016), %

(16%)

Gross profit (FY, 2016)

22.5 m

Gross profit margin (FY, 2016), %

59%

Net income (FY, 2016)

(32.2 m)

Market capitalization (16-Jun-2017)

83.8 m

Closing share price (16-Jun-2017)

2.9

Cash (31-Mar-2016)

26.6 m
Immunodiagnostic Systems's current market capitalization is £83.8 m.
£, GBPFY, 2014FY, 2015FY, 2016

Revenue

52.3 m45.4 m38.3 m

Revenue growth, %

(13%)(16%)

Cost of goods sold

16.7 m17 m15.8 m

Gross profit

35.6 m28.3 m22.5 m

Gross profit Margin, %

68%62%59%

Operating expense total

27.3 m25.1 m59.3 m

Pre tax profit

8.3 m4.1 m(37 m)

Net Income

7 m2.4 m(32.2 m)
£, GBPFY, 2014FY, 2015FY, 2016

Cash

26.7 m23.7 m26.6 m

Accounts Receivable

5.2 m5.4 m5.3 m

Current Assets

42.5 m40.7 m43.3 m

PP&E

11.2 m10.7 m9.9 m

Goodwill

48.7 m45.9 m9.2 m

Total Assets

102.5 m97.2 m62.5 m

Accounts Payable

1.9 m2.1 m1.5 m

Current Liabilities

7.8 m7.3 m6.7 m

Retained Earnings

6.1 m(127 k)(33 m)

Total Equity

86.6 m80.4 m51.6 m

Financial Leverage

1.2 x1.2 x1.2 x
£, GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

12.3 m8.8 m8.2 m

Cash From Financing Activities

854 k(2.6 m)(985 k)

Income Taxes Paid

(1.4 m)(1.7 m)4.9 m
£, GBPY, 2016

Revenue/Employee

114 k

Financial Leverage

1.2 x

Immunodiagnostic Systems Market Value History

Immunodiagnostic Systems Online and Social Media Presence

Immunodiagnostic Systems Company Life and Culture

You may also be interested in